FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.
You may also be interested in...
The 2017 user fee reauthorization bill contains provisions that should be significantly easier for the agency to implement compared with the 2012 measure. Senate clears clean bill for president's review.
FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?
US FDA cut first-cycle review time 46% between fiscal year 2013 and FY 2015, but more than 900 ANDAs still awaited review by end of 2016.